Last reviewed 2026-04-22 · How we verify

EYP-1901

EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye.

EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye. Used for Dry eye disease, Anterior uveitis.

At a glance

Mechanism of action

EYP-1901 is a refillable intracameral implant that provides long-term delivery of a corticosteroid to treat inflammatory eye conditions. The implant is placed in the anterior chamber of the eye and can be refilled to maintain therapeutic drug levels, reducing the need for frequent topical eye drops and improving patient compliance.

Approved indications

• Dry eye disease
• Anterior uveitis

Common side effects

• Elevated intraocular pressure
• Cataract formation
• Implant-related complications

Key clinical trials

• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (PHASE3)
• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (PHASE3)
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 (PHASE3)
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 (PHASE3)
• Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (PHASE2)
• Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) (PHASE2)
• Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (PHASE2)
• First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.